Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $577.4 million.

  • Dianthus Therapeutics' Liabilities and Shareholders Equity rose 63.01% to $577.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 26.54%. This contributed to the annual value of $374.0 million for FY2024, which is 108.47% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Liabilities and Shareholders Equity of $577.4 million as of Q3 2025, which was up 77.09% from $326.1 million recorded in Q2 2025.
  • Dianthus Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $577.4 million during Q3 2025, with a 5-year trough of $78.6 million in Q2 2023.
  • Over the past 3 years, Dianthus Therapeutics' median Liabilities and Shareholders Equity value was $348.6 million (recorded in 2025), while the average stood at $296.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 57.07% in 2023, then surged by 369.19% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $83.1 million in 2022, then surged by 115.86% to $179.4 million in 2023, then spiked by 108.47% to $374.0 million in 2024, then surged by 63.01% to $577.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $577.4 million for Q3 2025, versus $326.1 million for Q2 2025 and $348.6 million for Q1 2025.